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ABSTRACT  
Objective: To investigate research professionals’ perspectives regarding minority participation in clinical 
trials. 
 
Methods: A web-based survey of research professionals at US institutions receiving NIH and/or AHRQ 
funding to conduct clinical research in 2013. Descriptive statistics, mean, standard deviation (SD) and the 
Wilcoxon rank sum test were utilized for analysis. 
 
Results: Distributed were 13,041 surveys with 967 (7.4%) responses. Overall and race-stratified analyses 
included 633 and 521 surveys, respectively. A majority agreed that patients’ race (mean 3.4, SD=1.0) and 
primary language (mean 4.0, SD=0.9) have an effect on enrollment. They had more success in enrolling 
those whose primary language was the same as their own (mean 3.8, SD=1.0), and that a language barrier 
and time spent arranging for interpreters had prevented them from offering a study to potential candidates 
(mean 3.2, SD=1.2).  
 
Non-Caucasian respondents were more likely to agree that “fear of unknown side-effects” was a deterrent 
for minorities (p<0.01), “minorities are more likely to be unavailable for follow-up phone calls” (p=0.07), 
and “the unavailability of translated material discourages non-English speakers from participation” 
(p=0.08). They also were more likely to be neutral or agree with being discouraged from enrolling 
minorities because of the possibility of their withdrawal, or being less likely to be available for phone 
follow-ups and follow-up visits (all p<0.01). 
 
Conclusion: Despite a few subtle racial differences in research professionals’ perspectives, a majority 
expressed no hesitation in enrolling minorities. Patients’ race and primary language appeared to influence 
enrollment. A language barrier appeared to be the strongest barrier for research professionals. 
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INTRODUCTION   
Diversity and equity in clinical trial participation are essential to ensure the safety and efficacy of 
investigational drugs and devices. Although scientific evidence demonstrates physiological and metabolic 
differences among many racial and ethnic sub-populations [1-3], demographics in the United States (US) 
are not replicated in clinical trial participation and minorities remain under-represented in research [4-6].  
 
The existing literature primarily discusses barriers to participation from minority patients’ perspectives 
[7-11], and also suggests racial disparities in clinical trials are partly due to minorities’ own unwillingness 
to participate [9, 10]. However, it has been reported that unequal treatment of minorities may be due to 
the fact health care providers harbor prejudicial attitudes, which may influence their decision about 
treatment [12-16]. In addition to Wendler, et al., demonstrating that when invited to volunteer for 
research, minority patients were significantly more likely to consent than for non-minority patients [17], a 
recent study reported racial differences in oncologist-patient communication about clinical trials. Visits 
with African-American patients compared to visits with White patients included fewer mentions of and 
less discussion of clinical trials [18]. Therefore, racial disparities in clinical trials seen today should not be 
viewed solely as an aftermath of previous negative experiences with racially-tinged research such as the 
Tuskegee trial [19], or the result of minorities’ personal unwillingness to participate, as long as other 
problematic issues have been addressed.  
 
Enrollment is primarily done by study investigators, research nurses and research coordinators. 
Unfortunately, there is a lack of information about barriers to minority participation from the perspective 
of enrolling research professionals [20-23] and whether or not disparities seen in clinical trials may also 
be a result of unconscious bias among these researchers [18, 23]. 
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As the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH) 
mandate an enrollment plan from their grantees for inclusion of diverse research populations [24, 25], 
research professionals from NIH- and/or AHRQ-funded institutions should be a robust cohort from which 
to learn their perceptions, barriers and recommendations regarding minority participation in clinical trials. 
The current study examines results from a survey of research professionals who actively enrolled patients 
and belonged to US institutions that received clinical research grants in 2013 from the NIH and/or 
AHRQ. 
 
We hypothesized that 1) research professionals would be generally hesitant to approach minorities for 
participation; and 2) there would be differences between Caucasian and non-Caucasian research 
professionals’ perspectives and barriers to enrolling minority patients. 
 
METHODS 
Compliance with Ethical Standards 
This study was approved by our network’s Institutional Review Board (IRB) as exempt research. 
 
Study Design and Population 
Based on an extensive review of the literature, a survey was developed by the Principal Investigator and 
distributed to a group of statisticians and local clinical investigators. Based on their feedback, the survey 
was revised and IRB approval was obtained for this study. Next, it was randomly piloted among 15 local 
research professionals. We did not disclose the purpose of the study during the validation process to 
prevent any bias from these pilot participants. This was simply to test how specific our survey instrument 
was, especially being the first of its kind in this field. A brief questionnaire was given to these pilot 
subjects asking whether they could identify what the purpose of our survey was and to also provide 
general feedback. All respondents accurately concluded that the survey was meant to investigate the 
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underlying reasons for disparities in research. Revisions were made to incorporate their suggestions and 
feedback before distributing the survey to the target population.  
 
We identified those hospitals, schools of public health and medical schools that received NIH and/or 
AHRQ funding in 2013 to conduct clinical trials, and collected the contact information (email and postal 
mailing addresses) of research professionals listed on their respective institutions’ websites. The survey 
was emailed (via Qualtrics, Provo, UT) to this population in June, 2015 and was designed for completion 
in approximately seven to eight minutes. Two successive email reminders that contained a link to the 
survey were sent at two-week intervals. As an incentive for research staff to complete the survey, we 
randomly picked 100 respondents to each receive a $50 gift card. This information and the purpose of the 
study, along with the voluntary and anonymous nature of the survey, were mentioned on the introductory 
page of the survey. Gift cards were issued to those randomly chosen in September of 2015.  
 
Variables 
Participant and workplace characteristics used in this study included: Professional role, gender, race, 
workplace description, whether respondent enrolls subjects in clinical trials, and whether the respondent 
works on federally-funded research. Based on their research experience, respondents were asked 
questions about their perceptions of what discourages minorities from participating in clinical trials versus 
what discourages research professionals themselves from enrolling minorities. Participants were also 
asked to identify any secular trends they have witnessed in research, what resources would be helpful to 
them, and what recommendations they have to promote diversity and equity in research. Questions were 
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Data Analysis 
Summary statistics were used to describe study participants and survey responses. Descriptive statistics 
and relative frequencies were used to summarize categorical variables. Chi-square tests were used to 
evaluate the distribution of participant and workplace characteristics by participant’s race. The Wilcoxon 
rank sum test was used to assess differences in sample distributions between participants’ reported race. 
Participants who responded "prefer not to answer" for the race/ethnicity question were excluded from the 
race-stratified analysis. All data management and analyses were performed by Stata V.12.1, Stata 
Corporation, College Station, TX [26].  
 
RESULTS 
Of the 13,041 research professionals who were emailed surveys, 967 (7.4%) responded (Figure 1). After 
excluding those 334 (34.5%) who did not actively enroll subjects in clinical trials, 633 respondents’ data 
were analyzed for the survey items that focused on general trends, helpful tools and their 
recommendations. For race-stratified analysis, we further excluded those 113 (17.8%) who either did not 
mention their race, or "preferred not to answer." The resulting dataset for analysis included 520 survey 
responses, of which 433 (83.3%) categorized themselves as “Caucasian” and 87 (16.7%) belonged to 
minority races such as Asian (n=45), African American (n=19), multi-racial (n=9), Hispanic (n=6), 
Native American (n=2) and other (n=6). Because of this low participation rate from minority respondents, 
data for each individual minority race could not be stratified separately and were merged into one 
category, “non-Caucasians.” 
 
We compared those participants who preferred not to identify their race and who skipped this question 
with the remainder of the cohort for the other self-classifying categories. Respondents with missing race 
information were slightly more likely to be study investigators (71.4%, n=80), than those with non-
missing information on the employment category question (63.1%, n=329, p=0.09). No differences were 
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observed for these individuals when comparing whether their studies were federally funded (72.3% versus 
75.2%, p=0.52), whether they worked at academic institutions (67.9% versus 70.8%, p=0.53), or the total 
number of research studies enrolling participants categorized as “3 or more” (36.6% versus 40.9, p=0.40) 
(data not presented in table form).  
 
Table 1 presents the distribution of respondents’ professional and demographic characteristics by race. 
Although no differences were observed in the distributions of professional title, type of institution, total 
number of enrolling studies, or whether their research was professionally funded, non-Caucasian 
respondents were more likely to be female (72.4% versus 62.4%, p=0.07), less likely to report English as 
their primary language (84.1% versus 97.4%, p<0.01), and less likely to report fluency in only one 
language (62.1% versus 78.8%, p<0.01) compared to Caucasian respondents. 
 
Table 2 shows trends witnessed by research professionals in clinical trials. A majority agreed that 
patients’ race (mean 3.4, SD=1.0) and primary language (mean 4, SD=0.9) have an effect on enrollment 
success. The majority also indicated they had more success with enrolling subjects whose primary 
language was the same as theirs (mean 3.8, SD=1.0). Further, they agreed that a language barrier, as well 
as time spent on arranging for interpreters, had prevented them from offering a study to potential 
candidates (mean 3.2, SD=1.2).  
 
The distributions of participant responses about their perception of barriers to minority participation and 
their own barriers to enroll minorities were race stratified (Tables 3a and 3b, respectively). Respondents 
agreed that all barriers listed in the survey tend to discourage minority participation in clinical trials 
(Table 3a). However, non-Caucasian respondents were more likely to agree that “fear of unknown side 
effects” was a significant deterrent for minority participation (p<0.01). Non-Caucasian research 
professionals were also marginally more likely to agree or strongly agree with the statements that 
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“minorities are more likely to be unavailable for follow-up phone calls” (p=0.07) and that the 
unavailability of translated material discourages non-English speakers from participation (p=0.08). 
 
Factors that may discourage research professionals from enrolling minorities in clinical trials are 
presented in Table 3b. The respondents did not agree with any of the deterring factors listed in the survey 
that might make them hesitate to enroll minorities, with median responses all falling in the “strongly 
disagree” to “disagree” range. However, subtle differences in some factors were observed between 
Caucasian and non-Caucasian respondents. Non-Caucasian research professionals were more likely to be 
neutral or agree that they are discouraged from enrolling minorities because of the possibility of their 
withdrawal from participation (p<0.01), and decreased availability for phone follow-ups (p<0.01) and 
multiple follow-up visits (p<0.01). 
 
Regarding the potential tools/resources helpful in training researchers to enroll diverse populations, a 
majority of research professionals preferred mentoring from experienced investigators (mean 3.6, 
SD=1.1) (Table 4). Recommendations from research professionals on how federal agencies should hold 
grant recipients accountable for enrollment plans are categorized in Table 5. A majority recommended 
checking with grantees annually to determine whether actual enrollment matched the proposed enrollment 
plan and to ask for effective strategies for improvement, as needed (mean 3.5, SD=0.9). 
  
DISCUSSION 
While birth and immigration trends predict that non-Caucasians will encompass up to 50% of the US 
population by 2044 [27], they continue to be underrepresented in clinical trials [4-6]. While a plethora of 
studies have focused solely on minority patients’ perspectives regarding their participation in clinical 
trials [7-11], researchers’ perspectives and barriers in enrolling minorities remain understudied and 
Page 10 of 19 
 
ignored. We agree that empowering both potential enrollees and enrollers is equally important in 
resolving racial disparities in clinical trials [23].  
 
Existing literature suggests that the investigator being the same race as a potential study subject appears to 
be more motivating to minorities’ participation and recommends encouraging more minority investigators 
[9, 11, 28-30]. Also suggested is educating investigators about their own cultural awareness and 
sensitivity, so they can interact more successfully with minority patients [10, 31, 32]. Our data show even 
though the majority of respondents agree that race and ethnicity of potential candidates have an effect on 
enrollment success, they did not indicate they were more successful in enrolling subjects of their own 
race. In the current study, the language spoken by patients and research professionals appeared more of an 
important factor in enrollment than race. A majority of respondents agreed not only that a patient’s 
primary language had an effect on enrollment success, but research professionals had more success 
enrolling subjects who shared their primary language. Further, a majority indicated that the language 
barrier and time spent arranging for interpreters had, in fact, prevented them from offering a study to 
potential candidates. It is noteworthy that over 95% of our respondents listed English as their primary 
language. Several reports have indicated that language is a barrier to the non-English speaking 
population’s participation in research [7, 8, 11]. One possible response to this common issue is to require 
the costs of translating study materials and hiring interpreters be included in a study’s budget at the time 
of submission. 
 
In contrast to Caucasians, non-Caucasian research professionals were more likely to report that in their 
experience, the fear of unknown side effects, availability for follow-up telephone calls and unavailability 
of translated material discourages minority patients from participation. Although these barriers are widely 
reported in the literature from minority patients’ perspectives [11, 29, 33] and are in agreement with our 
non-Caucasian research professionals’ experience, the reasons for Caucasian research professionals not 
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experiencing or ranking these barriers at the same level as non-Caucasian research professionals are not 
clear.  
 
Furthermore, data show that compared to Caucasians, non-Caucasian research professionals were more 
likely to report having been discouraged from enrolling minorities due to the possibility of their 
withdrawal, as well as their unavailability for telephone follow-ups and multiple follow-up visits. This 
finding is critical considering that a potential subject should be excluded from research only if he/she was 
clinically ineligible. No research subject should be excluded from study participation because they might 
withdraw or did not have a telephone or transportation for follow-up purposes. Options to address these 
concerns include funding for subjects to make a collect call or providing a phone card, and arranging 
transportation for subjects or have research nurses drive to participants’ place of residence for follow-ups, 
an approach widely used by home care nurses. 
 
The current study demonstrates that the majority of research professionals think mentoring by 
investigators experienced in enrolling diverse populations would increase their own success in enrolling 
diverse populations. Although it is important to train minority physicians as investigators in order to 
promote diversity in research [34, 35], it is equally important that research professionals of all ethnicities 
are mentored and receive training to enhance their cultural competence and ability to enroll diverse 
populations [10, 32]. Of note, when compared to Caucasians, more non-Caucasian research professionals 
reported having been discouraged from enrolling minority patients. 
 
The current results indicate that asking institutions to provide a plan for enrolling diverse populations 
when applying for federal funding may not be enough. Study participants recommended that in order to 
hold grant recipients accountable for their enrollment plan, granting agencies should check annually 
whether recipients’ enrollment matches their proposed plan; if not, the agencies need to request effective 
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strategies for improvement. This would motivate and enable grant recipients to enroll the number of 
minority participants projected in their enrollment plans. 
 
Interestingly, a majority of our respondents did not agree that further/successive funding should be 
contingent upon having complied with prior enrollment plans for diverse populations. Nor did they agree 
with the suggestion that a drug or device should be approved only for those populations that were 
proportionally included in a clinical trial representing US demographics. Because multiple reports have 
shown race and sex differences exist in drug metabolism [1-3], we anticipated research professionals 
would favor approval of drugs and devices only for those populations that were adequately represented in 
a trial. The majority of our respondents were Caucasian investigators enrolling patients in federally-
funded studies; the number of minority respondents was low, indicating there is a racial disparity at the 
level of research professionals themselves [36]. A large-scale study including an equal representation of 
genders, races and research roles may shed more light on barriers to enrolling minorities in clinical trials.  
 
Strengths and Limitations 
Our strategy of surveying only research professionals whose institutions received either AHRQ and/or 
NIH funding in 2013 was based on the fact that these organizations specifically encourage enrollment of 
women and minorities in clinical research [24, 25]. Since these individuals are expected to more 
rigorously reach out to diverse populations for participation, learning from their experiences made this 
investigation a strong one.  
 
In contrast to a previously published study focused only on those investigators who had received funding 
from the National Heart, Lung, and Blood Institute [37], ours was the first nationwide study of research 
professionals who were actively enrolling patients and whose institution had received NIH and/or AHRQ 
funding. Therefore, this study covers a wide range of medical specialties. Ours took a novel approach in 
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comparing research professionals’ perceptions about what prevents minorities from enrolling in clinical 
trials versus what prevents researchers from enrolling minorities. This is also the first study asking 
researchers about their suggestions for helpful resources and recommendations to resolve disparities in 
clinical trials. 
 
Despite a $50 gift card incentive and two email reminders, our response rate was only 7.4% for this 
anonymous survey, which required seven to eight minutes to complete. This disappointing response may 
be due to the somewhat sensitive nature of the questions and hesitancy to admit biases. Further, this low 
response from a target population of researchers, who might be expected to exhibit high levels of interest 
in this topic, may be due to the email survey method we utilized. Although we targeted researchers 
affiliated with institutions receiving NIH and/or AHRQ funding, it is likely that our email list also 
included some bench or qualitative researchers at these institutions and would have lowered the overall 
response rate. Further, those who participated due to their personal interest in this topic may have 
introduced some bias in this self-selected sample. 
 
We were interested in exploring variations in perceptions of research professionals from different racial 
backgrounds. However, in addition to a low response rate, 17.7% of respondents (primarily investigators) 
did not respond to the question of race which further decreased our ability to quantify these differences. 
While investigating researchers’ perspectives regarding barriers to each individual minority race should 
be explored, we did not pursue this approach as we were concerned about the length of the survey further 
lowering its response rate. 
 
CONCLUSION 
Despite a few subtle racial differences in research professionals’ perspectives regarding minority patients’ 
barriers, as well as in their own barriers to enrolling minorities, a majority reported no hesitation in 
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enrolling minorities. Patients’ race and primary language appeared to influence enrollment. The language 
barrier appeared to be the strongest for research professionals when considering enrolling minorities. To 
promote diversity in clinical trials, a majority recommended mentoring from investigators experienced in 
successfully enrolling diverse populations and an annual check by federal agencies to hold grant 
recipients accountable for their enrollment plan. 
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Table 1:  Respondents’ characteristics stratified by race (N=520). 




N (%) p-value* 
What is your role in clinical 
research? 
Investigator 329 (63.3) 277 (64.0) 52 (59.8) 
0.20 
Clinical Research Coordinator 81 (15.6) 65 (15.0) 16 (18.4) 
Research Nurse 17 (3.3) 15 (3.5) 2 (2.3) 
Research Associate 15 (2.9) 9 (2.1) 6 (6.9) 
Research Assistant 5 (1) 4 (0.9) 1 (1.2) 
Other 18 (3.5) 14 (3.2) 4 (4.6) 
Combination 55 (10.6) 49 (11.3) 6 (6.9) 
What type of institution do 
you currently work at? 
Academic hospital 369 (71) 303 (69.8) 66 (76.7) 
0.32 
Community hospital 29 (5.6) 26 (6.0) 3 (3.5) 
Academic Community hospital 70 (13.5) 58 (13.4) 12 (14) 
Government/VA Facility 6 (1.2) 5 (1.2) 1 (1.2) 
Other 23 (4.4) 19 (4.4) 4 (4.7) 
Multiple 23 (4.4) 23 (5.3) 0 (0) 
How many clinical research 
studies have you been 
enrolling for within the last 
five years? 
None 7 (1.3) 4 (0.9) 3 (3.5) 
0.14 1-5 301 (57.8) 249 (57.4) 52 (59.8) 
6 or more 213 (40.9) 181 (41.7) 32 (36.8) 
Were any of the studies 
federally funded? 
Yes 392 (75.4) 328 (75.8) 64 (73.6) 
0.86 No 119 (22.9) 98 (22.6) 21 (24.1) 
Don’t know 9 (1.7) 7 (1.6) 2 (2.3) 
What is your gender? 
Female 333 (64.0) 270 (62.4) 63 (72.4) 
0.07 
Male 187 (36.0) 163 (37.6) 24 (27.6) 
What is your primary 
language? 
English 480 (95.2) 411 (97.4) 69 (84.1) 
<0.01 
Other 24 (4.8) 11 (2.6) 13 (15.9) 
Total languages spoken? 
1  396 (76.0) 342 (78.8) 54 (62.1) 
<0.01 2 116 (22.3) 85 (19.6) 31 (35.6) 
3+ 9 (1.7) 7 (1.6) 2 (2.3) 
        *p-values are based on Chi-square tests. 
 
 
Table 2:  Responses for, “Based on your past experience, what trends have you witnessed in clinical research?” 













Patients with higher education are more likely to participate. 583 3.3 1.0 14 137 141 236 55 
Patients with higher income are more likely to participate. 580 2.9 0.9 25 182 213 134 26 
Patients with private insurance are more likely to participate. 580 2.9 0.8 23 160 291 89 17 
Race and ethnicity of the potential candidate have an effect 
on enrollment success. 581 3.4 1.0 17 111 150 240 63 
The primary language spoken by the potential candidate has 
an effect on enrollment success. 580 4.0 0.9 9 33 84 275 179 
I have more success enrolling those who are the same 
race/ethnicity as me. 580 2.7 0.9 58 198 213 100 11 
I have more success enrolling those whose primary language 
is the same as mine. 580 3.8 1.0 18 57 120 239 146 
A language barrier and time spent arranging for interpreters 
have prevented me from offering a study to potential 
candidates. 
578 3.2 1.2 55 127 124 175 97 
*SD=Standard Deviation 
 
Table 3a: Summary statistics and distribution of responses for, “Based on your past experience, what discourages minorities from participating in clinical 
research?” 











Distrust in doctors Caucasian 425 3.4 1.0 10  78  92  204  41  
0.34 Non-Caucasian 87 3.5 1.0 1  18  13  43  12  
Fear of unknown side effects Caucasian 425 3.5 0.9 10  52  119  210  34  
<0.01 Non-Caucasian 85 3.8 0.9 2  6  14  45  18  
Unavailability for multiple follow-up visits Caucasian 427 3.6 0.9 4  55  95  212  61  
0.16 Non-Caucasian 87 3.8 1.0 2  9  14  45  17  
Unavailability for phone follow-ups Caucasian 428 3.1 0.9 14  103  152  137  22  
0.07 Non-Caucasian 87 3.3 1.0 1  21  23  32  10  
Unavailability of translated material for 
non-English speakers 
Caucasian 429 3.5 1.0 14  69  107  169  70  
0.08 Non-Caucasian 87 3.7 1.0 1  14  13  41  18  
Unavailability of medical interpreters 
Caucasian 429 3.3 1.0 16  81  122  156  53  
0.16 Non-Caucasian 87 3.5 1.0 1  17  21  31  17  
*SD=Standard Deviation 
#p-value based on the two-sample Wilcoxon rank-sum test. 
 
Table 3b: Summary statistics and distribution of responses for “Based on your past experience, what discourages you from enrolling minorities?” 














I hesitate to enroll minorities. Caucasian 430 1.3 0.6 330  76  18  5  1 
0.01 Non-Caucasian 86 1.5 0.8 55  19  8  4  0  
My fear that I won’t be trusted discourages me from 
enrolling minorities. 
Caucasian 429 1.4 0.8 307  86  21  14  1  
0.09 Non-Caucasian 84 1.6 0.9 53  19  8  4  0  
The possibility of their withdrawal discourages me from 
enrolling minorities. 
Caucasian 429 1.4 0.8 298  88  25  17  1  
<0.01 Non-Caucasian 86 1.8 1.0 45  19  14  8  0  
The possibility of their unavailability for multiple follow-
up visits discourages me from enrolling minorities. 
Caucasian 431 1.6 1.0 278 81 35 36 1 
<0.01 Non-Caucasian 85 2.0 0.1 41 19 13 11 1 
The possibility of their unavailability for phone follow-
ups discourages me from enrolling minorities. 
Caucasian 429 1.5 0.9 286  82  38  22  1  
<0.01 Non-Caucasian 85 1.9 1.0 41  22  15  6  1  
*SD=Standard Deviation 
#p-value based on the two-sample Wilcoxon rank-sum test. 
 
 
Table 4: Responses for, “Which of the below tools would be helpful in training you regarding how to enroll diverse populations?” 
















DVDs demonstrating how to approach each specific 
racial/ethnic group 
 
528 3.1 1.1 66  78  154  201  29  
 
Mentoring from investigators experienced in 
enrolling diverse populations 
 
528 3.6 1.1 36  41  100  266  85  
 
Mock enrollment sessions targeting specific 
populations 
 





Table 5:  Summary statistics and distribution for, “What would you recommend federal agencies do to hold grant recipients accountable for their 
enrollment plan?” 
 














Check annually if actual enrollment matches with 
the proposed plan and ask for effective strategies, 
as needed. 
 
526 3.5 0.9 24  54  108  299  41  
Award further/successive funding only if the 
enrollment plan for diverse populations was met. 
 
526 2.7 1.1 85  151  133  141  16  
Approve a drug/device only for those populations 
that were proportionally included in a trial 
representing demographics of the United States. 
 
524 2.7 1.1 87  155  144  118  20  
*SD=Standard Deviation 
 
 
